Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients by Ademowo, OS et al.
Contents lists available at ScienceDirect
Free Radical Biology and Medicine
journal homepage: www.elsevier.com/locate/freeradbiomed
Original article
Phospholipid oxidation and carotenoid supplementation in Alzheimer’s
disease patients
O.S. Ademowoa, H.K.I. Diasa, I. Milica, A. Devitta, R. Moranb, R. Mulcahyc, A.N. Howardd,e,
J.M. Nolanb, H.R. Griﬃthsa,f,⁎
a Life & Health Sciences, Aston University, Birmingham, UK
b Nutrition Research Centre Ireland, Health Science, Waterford Institute of Technology, Cork Road, Waterford, Ireland
c Waterford University Hospital, Age-related Care Unit, Waterford, Ireland
d Howard Foundation, Cambridge, UK
e Downing College, University of Cambridge, Cambridge, UK
f Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
A R T I C L E I N F O
Keywords:
Oxidative stress
Lipid peroxidation
POVPC
Mass spectrometry
Lutein
Meso-zeaxanthin
Zeaxanthin
Supplementation
Cognitive function
A B S T R A C T
Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory,
cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD and
reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are
depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control
subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-
(5′-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionisation tandem mass
spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and
ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay.
AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either
Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunﬂower oil) for six months.
The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly
(CV=7.9%). At baseline, AD subjects had higher serum POVPC compared to age-matched controls,
(p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months
of carotenoid intervention, serum POVPC was not diﬀerent in AD patients compared to healthy controls.
However, POVPC was signiﬁcantly higher in control subjects after six months of carotenoid intervention
compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation.
Serum FRAP was signiﬁcantly lower in AD than healthy controls but was unchanged by carotenoid intervention
(p=0.003).
In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by
carotenoid supplementation and correlates with cognitive function.
1. Introduction
Alzheimer's disease (AD), the most common form of dementia, is a
degenerative brain disorder characterised by chronic and disabling
memory loss with cognitive impairment. Cognitive decline begins
before appearance of the dementia syndrome [1,2] and shares common
features with AD and the ageing brain [2].
Post-mortem investigations of aﬀected brain regions have shown the
accumulation of oxidative damage to protein, DNA and lipids in AD and
oxidative stress has been considered as important in the pathogenesis of
AD [3,4].
Non-enzymatic peroxidation of polyunsaturated fatty acids is
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mediated by reactive oxygen species (hydrogen peroxide, hydroxyl
radicals, nitrogen dioxide and hypohalous acids) and yields diﬀerent
peroxidation products such as hydroperoxides and truncated lipid
species e.g. carbonyl compounds such as malondialdehyde [5,6]. Many
lipid hydroperoxides, including oxidised phospholipids (oxPLs), are
considered to be biologically relevant lipid signalling molecules [7,8].
However, oxPLs are usually low in abundance and pose some chal-
lenges in detection, identiﬁcation and quantiﬁcation [5]. To address
this, liquid chromatography-mass spectrometry (LC-MS) techniques are
emerging for reliable detection and quantiﬁcation of wide range of
oxPLs [6,9]. Lipidomics, a robust method for lipid analysis, has been
deﬁned as the characterisation of lipids in biological systems [10].
Oxidative lipidomic techniques oﬀer sensitive and speciﬁc methods for
high throughput analyses of oxPLs [11] such as 1-palmitoyl-2-(5′-oxo-
valeroyl)-sn-glycero-3-phosphocholine (POVPC) and fatty acid oxida-
tion, such as 8-iso-PGF2a (IsoP) [4]. POVPC is a truncated oxidation
product of 1-palmitoyl-2-arachidonoyl-sn-phosphatidylcholine (PAPC);
and IsoP belongs to the prostaglandin family that is formed by free
radical peroxidation of arachidonic acid in membrane lipids. IsoP is a
relatively stable peroxidation product compared to many other short
lived species [12]. POVPC and IsoP are considered as biomarkers of
oxidative stress [13–15].
Oxidative stress has been deﬁned as the imbalance between the pro-
oxidant and antioxidant status favouring the pro-oxidant state [4].
Ferric reducing antioxidant potential (FRAP; the ferric reducing ability
of the serum and a measure of total antioxidant capacity) has been
reported to be lower in AD patients compared to healthy controls
[16,17]. Carotenoids are naturally occurring plant pigments, some of
which have antioxidant properties [18,19]. Higher plasma carotenoid
concentrations are associated with reduced risk of developing chronic
disease [20]. They are lipid soluble, are transported principally by
lipoproteins and can be broadly classiﬁed as either oxygenated
xanthophylls or non-oxygenated carotenes [21]. Several authors have
shown a signiﬁcantly lower serum concentration of carotenoids (lutein,
zeaxanthin and meso-zeaxanthin) in AD subjects [22–24] which can be
increased after 6 months of supplementation with carotenoids [25].
Therefore, we have investigated the hypothesis that POVPC is a
modiﬁable marker of AD that relates to cognitive performance. In this
study, we describe the development of a method for sensitive detection
of POVPC in serum. We have compared the levels of POVPC, IsoP and
FRAP in serum from AD patients and healthy age-matched controls
before and after six months of carotenoid supplementation in a double-
blind study.
2. Materials and methods
Macushield™, a soft gel capsule active supplement containing 10 mg
meso-zeaxanthin;10 mg lutein; 2 mg zeaxanthin was purchased from
Macuvision Europe Ltd. (Blythe Valley Innovation Centre, Central
Boulevard, Solihull, United Kingdom). Authentic standards of 1-palmi-
toyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) and
non–naturally occurring deuterated internal standard (ISTD) 1-palmi-
toyl-d31-2-oleoyl-sn-glycero-3-phosphocholine (dPOPC) were pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA). HPLC grade
water and solvents were purchased from Fisher Scientiﬁc
(Loughborough, UK). All other chemicals were purchased from
Sigma–Aldrich (Dorset, UK) unless otherwise stated.
2.1. Standard solutions
The stock solutions of phospholipids were prepared at 1 ng/µl in 2-
propanol and stored at −20 °C. A mixture of POVPC and dPOPC (each
0.1 ng/µl) was used for the optimisation of the LC-MS/MS(MRM)
method.
2.2. Subject recruitment
We analysed serum samples from a random subset of AD patients
(n=21) and healthy subjects (n=16) who participated in the
Carotenoid and AGE-Related Dementia Study (CARDS) at the
Nutrition Research Centre Ireland (NCRI). Samples for this study were
part of a randomised double-blind clinical trial investigating the eﬀect
of macular carotenoid supplementation on macular pigment (MP),
vision and cognitive function in patients with AD versus control
subjects. Patients with mild to moderate AD attending the Age-
Related Care Unit at Waterford University Hospital Ireland and healthy
control subjects with the same age range were recruited via the media.
Mild to moderate AD was deﬁned as an average Mini-Mental State
Examination (MMSE) score of 14–24, with some alteration in behaviour
as well as diﬃculties in carrying out day-to-day tasks. Cognitive
function was assessed with diﬀerent cognition tests which includes a
semantic ﬂuency score using ‘Animal’ category (as many examples in
one minute), and a phonemic ﬂuency score using the ‘FAS’ test (as
many words starting with letters F, A and S, one minute per letter). Full
details of the patient demography and health, study design and
methodology have been previously reported [26]. AD subjects and
healthy controls were supplemented with either 10 mg meso-zeax-
anthin, 10 mg lutein, 2 mg zeaxanthin in sunﬂower oil daily or placebo
(sunﬂower oil) for six months (double-blinded). The carotenoid and
placebo supplements were identical in external appearance (gel cap-
sules) and composition (sunﬂower oil with or without carotenoids) and
were therefore indistinguishable from each other. Patients who were
taking carotenoid supplements or had taken a supplement in the
previous 12 months were excluded from the study. Other screening
tests used for eligibility included the clock drawing test and semantic
ﬂuency score. Co-morbid diagnoses were documented and current
medications were veriﬁed including cholinesterase inhibitor use.
All protocols were approved by the local Waterford South East (of
Ireland) Region Ethics Committee prior to the commencement of the
study. Study design, subject recruitment, exclusion criteria, blood
sample collection/serum preparation methods as well as baseline/six
months carotenoid supplementation statistics for this patient cohort
have been previously reported by Nolan et al.(see [25,26]).
2.3. Extraction of lipids
Lipids were extracted from 10 µl of serum using the methyl-tert-
butyl ether (MTBE) lipid extraction method as previously described
[27]. Each serum sample was spiked with 4 ng ISTD (dPOPC) prior to
extraction. Brieﬂy, 375 µl ice-cold methanol containing 50 μg/ml of
BHT (0.005% BHT) was added to 10 µl serum in an eppendorf tube
containing 40 µl HPLC grade water and was vortexed. MTBE (1.25 ml)
was added, the samples were vortexed and transferred to a rotary
spinner at 40 rpm, 4 °C for 1 h. Phase separation was induced by adding
300 µl HPLC-grade water and samples were returned to the rotary
spinner for an additional 10 mins. The samples were centrifuged at
1000×g for 10 min and the upper (organic) phase was collected into a
new tube. The lower phase was re-extracted with 500 µl of the solvent
mixture in the ratio 10:3:2.5 v/v/v (MTBE/methanol/water). The
upper phase was collected and the combined organic phases were dried
in a vacuum concentrator and stored at−80 °C until ready for analysis.
The lipid extracts were reconstituted in 200 µl methanol prior to LC-MS
analysis.
2.4. Phospholipid assay
The phospholipid assay was performed according to Stewart [28]
with some modiﬁcations [44]. Brieﬂy, a standard curve of phosphocho-
line in the concentration range 5–50 µg/ml was made from 5 mg egg
yolk lecithin in chloroform. Ammonium ferrothiocyanate (0.1N; 1 ml)
was added to lipid solution (1 ml) in chloroform. A blank containing
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chloroform only (no PC standard or sample) was also analysed. After
vortexing, the lower (chloroform) layer was removed to a clean glass
tube, avoiding contamination with any of the aqueous layer. The
absorbance of the standards and samples were determined by a
spectrophotometer at 488 nm using quartz cuvettes.
2.5. MRM-MS method development for oxidised phospholipids
Mass spectrometric analyses were performed by a triple quadrupole-
linear ion trap mass spectrometer, QqLIT (QTRAP 5500, AB Sciex UK
Ltd., Warrington) equipped with a standard-ESI source, operated in a
positive ion mode with an ionisation voltage of 5.5 kV, entrance
potential of 10 V, and ion source temperature of 400 °C.
Optimisation of compound-speciﬁc precursor-to-fragment ion (Q1/
Q3) transition parameters (declustering potential, normalised collision
energy and quadrupole exit potential) was achieved by directly infusing
2 ng/µl POVPC and dPOPC standard solutions into the mass spectro-
meter using an integrated syringe pump (Harvard Apparatus) at a ﬂow
rate of 20 µl/min. The MRM method consisted of at least three most
intense PL-speciﬁc Q1/Q3 transitions (neutral loss of choline, -N(CH3)3,
−59 m/z units; neutral loss of PL-head group, -HPO4(CH2)2N(CH3)3,
−183 m/z units; PL-head group fragment ion at m/z 184) with the
dwell time of 50 ms. Final LC-MS/MS(MRM) analysis was performed by
on-line coupling of the LC (DIONEX UltiMate 3000, Thermo Scientiﬁc
UK Ltd., Hemel Hempstead) to the ESI-QqLIT-MS/MS. Relative quanti-
ﬁcation of POVPC in serum samples was based on the monitoring of m/
z 594/184 for POVPC and 791/184 for dPOPC, the ISTD, and
compound-speciﬁc retention times.
Lipid extracts (10 µl) were separated on an Acclaim C18 column
(internal diameter 2.1 mm, column length 150 mm, particle size 3 µm,
Thermo Scientiﬁc, UK) using the mobile phases consisted of (A) 10 mM
ammonium formate in methanol:water:formic acid (20:80:0.1, v/v/v)
and (B) 2 mM ammonium formate in 2-propanol:methanol:formic acid
(90:10:0.1, v/v/v) at 45 °C. Flow rate was maintained at 100 µl/min
with the gradient as follows: 30% B from 0 to 5 min, 30–70% B from 5
to 20 min, 70–100% B from 20 to 35 min, 100% B 35–40 min, 100–30%
B from 40 to 41 min, 30% B 41–51 min. The POVPC analyte eluted at
20.8 min while the ISTD, dPOPC eluted at 30.8 min.
2.6. MRM-MS method sensitivity and limit of detection
We determined the LOD and LOQ using the blank determination
method (n=20) from the ICH guidelines because our blank analysis
gave a non-zero standard deviation. LOD is expressed as the analyte
concentration corresponding to the sample blank value plus three
standard deviation. LOQ is reported as the analyte concentration
corresponding to the sample blank value plus ten standard deviations
[29].
2.7. Determination of linear dynamic range of oxidised phospholipid in
serum volumes
To create a sample pool for method development, 10 µl from each of
the serum samples were pooled together for use as a representative
sample. To establish the dynamic range for analysis, diﬀerent volumes
of the pooled sample (between 3 µl and 20 µl and equivalent to
~30–140 µg total phospholipids) were extracted. The lipid extracts
from the diﬀerent volumes were separated by HPLC and analysed by
the MRM-MS method. To ensure reproducible quantiﬁcation and to
minimise the risk of column saturation, a standard curve of volume of
serum versus POVPC intensity was produced. A consistent linearity that
corresponded to the middle of the linear dynamic range was determined
from 10 µl sera and this volume was selected for all future analyses.
This typically contained ~70 µg phospholipid.
2.8. Determination of the appropriate reference signal for data
normalisation
In the absence of commercially available isotopically labelled
POVPC, dPOPC was spiked into each sample to monitor for the
extraction eﬃciencies between samples. It was analysed within each
sample and used for the POVPC data normalisation. dPOPC (4 ng) was
reliably quantiﬁed and was co-extracted with the lipids within the
samples.
2.9. MRM–MS analysis of oxPLs
1-Palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphocholine
(POVPC), a product of non-enzymatic free radical PL oxidation, was
measured by MRM in serum from subjects before and after carotenoid
or placebo intervention. Lipid extracts were re suspended in methanol
(200 µl) and 100 µl from each lipid extract was pooled and used as the
quality control (QC) sample to monitor instrument performance during
analysis.
The MS data was manually inspected and integrated with the
Analyst software system (Version 1.5.1) using the corresponding Q1/
Q3 peak areas of POVPC and dPOPC. The response ratio of the POVPC
to the ISTD was calculated and the relative concentrations of POVPC in
samples were obtained.
2.10. Quality control
A pool of lipid extracts was analysed periodically (as detailed in
Table 2) to determine the reproducibility of the quantiﬁcations with
time by monitoring instrument performance over time. The CV was<
10% for repeated measures. Blanks (no biological material included)
were also prepared and analysed simultaneously and identically with
the rest of the set for QC purposes and to eliminate carry over. The
injection order was randomised.
2.11. Precision, accuracy and recovery
We determined the accuracy and the precision of the assay by
analysing the QC samples. Intra-day precision and accuracy were
evaluated by the analysis of six replicate samples. The inter-day
precision and accuracy were evaluated by analysing fourteen QC
replicates run on four consecutive days. Accuracy is required to be
within± 15% for QC samples [30]. Recovery was calculated for ﬁve
spiked POVPC concentrations (0.1, 0.5,1, 2 and 5 ng/ml) within the
linear dynamic range, and presented as a percentage of original
material.
2.12. Analysis of 8-isoprostanes
Total IsoP was measured in serum by ELISA (Abcam, Cambridge,
UK). Samples were prepared by acidiﬁcation then extracted using ethyl
acetate. Total IsoP was released by saponiﬁcation prior to analysis
according to the manufacturer's protocol.
2.13. Analysis of ferric reducing antioxidant potential
The ferric reducing antioxidant power (FRAP) was used to measure
the total antioxidant activity in the serum using the method described
by Benzie and Strain [16]. The FRAP assay is a redox-dependent
colorimetric assay [16].
2.14. Statistical analysis
Normality of the data distribution was assessed by Shapiro-Wilk
normality test. Paired t-tests were used to examine the eﬀects of
carotenoids intervention on serum oxPL, IsoP and FRAP levels.
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Unpaired t-test was used to compare the means of oxPL, IsoP and FRAP
levels in combined AD groups and combined control groups at baseline.
Correlations involving POVPC, 8-IsoP and FRAP were analysed by
Pearson's and Spearman's correlation as speciﬁed. Signiﬁcance was
accepted when p< 0.05. All statistical analyses were performed using
Prism statistical analysis software package (Version 7). G*Power soft-
ware (Version 3.1.9.2) was used to calculate the number of subjects
needed to attain 80% power with p< 0.05 based on the population
variance observed in this study.
3. Results
3.1. Patient details
Table 1 describes the demography, lifestyle and cognition data of
the AD and control subjects involved in the study. There were no
statistically signiﬁcant diﬀerences between groups in terms of age,
gender, body mass index, smoking status, diet score and education; cog-
nitive function was signiﬁcantly poorer in the AD population.
3.2. Optimisation of POVPC analysis by MRM-MS
The highest detection sensitivity for both POVPC and dPOPC was
achieved by monitoring precursor fragment ions of the PC head group
at 594/184 and 791/184 respectively. On examining the corresponding
Q1/Q3 transitions, the POVPC standard was shown to elute at 20.8 min
while the ISTD eluted at 30.8 min (Fig. 1a). The optimal volume of
serum needed for reliable measurement of POVPC within the linear
detection range was determined using a pooled serum collected from 20
individual subjects. Fig. 1b conﬁrms a linear dynamic range between 3
and 20 µl of serum, therefore the mid-range volume of 10 µl was
selected for patient and control serum analyses. The limit of detection
and the limit of quantiﬁcation were 5.4 pg and 7.5 pg for POVPC,
respectively. Analyte peaks were higher than the limit of detection.
3.3. Precision, accuracy and recovery
The analysis of the quality control samples was reproducible with a
coeﬃcient of variation of 7.94%. Table 2 conﬁrms that the instrument
performance was stable all through the sample analysis. Fourteen
replicates of the QC samples were used to evaluate precision and
accuracy level. The intra- and inter-day precision and accuracy values
of the QC samples are summarized in Table 2. The intra- and inter-day
precision and accuracy values for POVPC were acceptable (< 10%);
conﬁrming the accuracy and the reproducibility of the method.
Recovery was calculated for the four concentrations (from 0.5 to
5 ng/ml), and recoveries were between 20% and 30% for POVPC.
3.4. Serum lipid oxidation and antioxidant potential in AD
FRAP, IsoP and POVPC measurements in serum were normally
distributed. Fig. 2a–c illustrate signiﬁcantly higher concentrations of
POVPC (p=0.017) but not IsoP, and lower FRAP in AD patients
(p< 0.05). Pharmacological treatment has no eﬀect on serum POVPC
levels; 52% of AD patients were undergoing treatment with cholines-
terase inhibitors (CI) but there was no signiﬁcant diﬀerence between
serum POVPC levels in the group on CI medication and the group
without CI medication (p=0.26; Fig. 2d). POVPC, but not IsoP or FRAP
concentration, was correlated with MMSE (Fig. 2e–g); we observed a
Table 1
Demographic, lifestyle and cognition data of the AD and control subjects.
Variables AD Control p value
n=21 n=16
Demography
Age (years) 79± 8.8 75±6.6 0.24
Body mass index (kg/m2) 26.02± 3.6 25.96± 2.3 0.96
Exercise (total exercise, minutes
per week)
225.3± 253.7 220.9± 172 0.95
Diet (estimated lutein and
zeaxanthin intake)
17.2± 7.7 23.5± 13.1 0.07
Education (total years in
education)
11.45± 4.3 14.4± 4.0 0.04
Smoking (% current) 14% 19% 0.99
Gender (% female) 43% 50% 0.99
Diabetes (% with diabetes) 14% 19% 0.99
Cognition
MMSE 19±3.8 29±1.3 <0.0001
Semantic ﬂuency score 5.55± 2.65 15.6± 6.24 <0.0001
Phonemic ﬂuency score 16.9± 11.5 33.4± 13.3 0.0005
Data are reported as mean± standard deviation for interval data and percentages for
categorical data. AD subjects recruited into the study were conﬁrmed to have mild to
moderate Alzheimer's disease; age-matched control subjects were free of mild to moderate
AD. Signiﬁcant statistical diﬀerence (p value) between AD and control subjects was
assessed using independent samples t-tests; Exercise was measured as any sporting
activity per week; Diet was estimated as dietary intake of L and Z; Smoking was
categorized as current (smoked ≥100 cigarettes in lifetime and at least one cigarette
within the last 12 months) or non-smoking (smoked≤100 cigarettes in lifetime and none
within the last 12 months); Diabetes was conﬁrmed by self-report and by HbA1c analysis;
MMSE, Mini Mental State Examination; Semantic ﬂuency score, (categorical verbal
ﬂuency) score was obtained from the number of animals named by the subject in 1 min;
Phonemic ﬂuency score, (word ﬂuency) score was generated by the total number of words
produced for each of the letters F, A, and S, in 1 min.
Fig. 1. POVPC analysis by LC MS/MS using MRM. (a). Extracted ion chromatogram (XIC)
of PC head-group fragment m/z 184 for POVPC and dPOPC. The oxidised phospholipid,
POVPC, eluted at 20.8 min and the internal standard (deuterated POPC) eluted at
30.8 min. (b). Linear dynamic range of oxPLs in serum volumes. Lipids were extracted
from 3 to 20 µl serum and analysed in triplicates. 10 µl of serum sample was the ideal
volume selected for this study.
O.S. Ademowo et al. Free Radical Biology and Medicine 108 (2017) 77–85
80
negative Pearson's correlation (r=−0.37; p=0.04) between MMSE
score and POVPC, but not with IsoP and MMSE, r=−0.08 nor between
FRAP and MMSE, r=0.29 in AD patients. No correlation existed
between the measures of cognitive function, semantic ﬂuency (SVF)
score and POVPC (r =−0.05) nor between phonemic ﬂuency (FAS)
score and POVPC (r =−0.27) (Fig. 2h and i).
3.5. Cognitive function and the eﬀects of carotenoid supplementation
Semantic ﬂuency (SVF, p<0.0001) and phonemic ﬂuency (FAS,
p<0.001) scores were signiﬁcantly lower in AD patients at baseline
compared to age-matched healthy controls. Carotenoid supplementa-
tion using 10 mg meso-zeaxanthin;10 mg lutein; 2 mg zeaxanthin did
not have any eﬀect on cognitive performance in either group (Fig. 3a
and b).
3.6. Supplementation eﬀects on ferric reducing antioxidant potential
Serum FRAP was unchanged after either six months placebo or
carotenoid intervention in AD (Fig. 3c). There was no signiﬁcant
change in FRAP after either active or placebo supplement in the control
group (Fig. 3c).
3.7. Supplementation eﬀects on serum 8-isoprostane concentrations
There was no signiﬁcant diﬀerence between the serum concentra-
tions of IsoP in the healthy control and AD groups at baseline. After six
months of placebo and carotenoid intervention in AD, no diﬀerence was
observed in serum IsoP concentrations (Fig. 3d). In the control group,
mean IsoP concentration was increased almost two-fold with six months
of carotenoid supplementation (Fig. 3d), however, this eﬀect was not
statistically signiﬁcant.
3.8. Supplementation eﬀects on serum POVPC levels
There was no signiﬁcant diﬀerence between serum POVPC levels in
the AD group at baseline and the AD group after six months of placebo/
carotenoid intervention. However, there was a statistically signiﬁcant
increase in control group POVPC concentration after supplementation
with carotenoids for six months (p=0.03) (Fig. 3e).
4. Discussion
Phospholipids, especially phosphatidylcholine, are abundant serum
lipids that are easy to measure by MS due to their high ionisation
capacity. Recent studies have reported signiﬁcantly lower concentra-
tions of a number of phospholipids in blood from patients with AD [31].
We reasoned that the lower concentrations of circulating carotenoid
antioxidants in AD would predispose lipids to peroxidation and may
explain, at least in part, the diﬀerence in serum phospholipid proﬁle in
AD [23,31]. Here we have extended our earlier investigations that
showed an increase in the oxidative damage biomarkers isoprostanes
and protein carbonyls in vascular dementia [22,32] to determine
whether (1) oxPLs were increased in AD; (2) serum antioxidant
potential was lower and; (3) there was any relationship between oxPL
and disease activity.
Watson et al. measured diﬀerent oxPLs from human atherosclerotic
plaques and reported POVPC as the most abundant [33]. POVPC, a
truncated oxidation product of PAPC (1-palmitoyl-2-arachidonoyl-sn-
phosphatidylcholine), has been identiﬁed in vivo as an important
oxidised phospholipid [33]. We developed a reproducible and sensitive
method for quantitative analysis of POVPC by LC-MS/MS. LC-MS/MS
has been reported to be the best choice for the assay of diﬀerent oxPLs
[9] and we achieved sensitivity to detect POVPC from 10 µl serum using
a multiple reaction monitoring (MRM) method. At present, the lack of
speciﬁc oxidised phospholipid standards limits absolute quantiﬁcation
of some analytes such as POVPC by MS, however, relative quantitation
can be achieved accurately. Using this approach, we have shown here
for the ﬁrst time that the level of oxPL, POVPC, is two-fold higher in
serum from AD patients compared with age-matched healthy control
subjects.
The MTBE lipid extraction method used for lipid extraction in this
study allows faster and cleaner lipid recovery and is suitable for
lipidomics. We adapted the sample preparation described by Matyash
et al. [27] to extract, recover and preserve the phospholipid content
without oxidation. Serum lipids were recovered into the upper MTBE
phase of the 2-phase solvent system while non-extractable matrix were
in the aqueous phase retained at the bottom of the extraction vial.
Hence, the MTBE organic phase enriched with lipids is easily accessible
by micropipette from above without contamination. We demonstrated
the eﬀective recovery of oxPL in serum samples of AD patients and
control subjects using the MTBE method.
We were interested to understand whether POVPC was related to
cognition. We used the Mini Mental State Examination (MMSE),
‘Animal’ semantic ﬂuency (SVF) and ‘F A S’ phonemic ﬂuency scores
as the clinical parameters for scoring cognitive performance in AD and
to measure the eﬀect of carotenoid supplementation on cognitive
impairment (see [25]). These parameters were signiﬁcantly higher in
healthy controls compared to AD subjects with MMSE score correlating
with higher levels of oxPL. Pharmacological treatment with cholines-
terase inhibitor has no eﬀect on POVPC level in AD patients. There were
no signiﬁcant diﬀerences observed in the SVF and FAS scores of control
subjects or AD patients after supplementation compared to their
baseline readings. The present study has identiﬁed an inverse correla-
tion between POVPC and cognitive function in AD. These ﬁndings are
consistent with our earlier observation of an increase in plasma LDL
protein carbonyls that correlated inversely with MMSE in AD. We also
demonstrated that plasma malondialdehyde concentration was not
diﬀerent but that LDL oxidation in AD plasma was higher than in LDL
from age-matched control subjects [32] i.e. diﬀerent oxidative biomar-
kers are inversely correlated with cognitive function in two indepen-
dent dementia populations.
Table 2
POVPC analysis in quality control samples.
Quality
control
samples
Target lipid peak area Internal
standard peak
area
Normalised peak
area
1 6.26E+05 3.32E+06 6.26E+05
2 6.36E+05 3.02E+06 6.99E+05
3 5.80E+05 3.23E+06 5.96E+05
4 5.90E+05 2.96E+06 6.62E+05
5 5.84E+05 3.11E+06 6.23E+05
6 6.57E+05 2.86E+06 7.63E+05
7 6.48E+05 3.07E+06 7.01E+05
8 6.05E+05 3.04E+06 6.61E+05
9 5.83E+05 3.29E+06 5.88E+05
10 6.22E+05 3.53E+06 5.85E+05
11 6.69E+05 3.64E+06 6.10E+05
12 7.86E+05 3.97E+06 6.57E+05
13 7.75E+05 4.09E+06 6.29E+05
14 7.27E+05 4.01E+06 6.02E+05
QC sample number
(n)
Mean SE SD CV
Intra-day assay (6) 6.62E
+05
2.54E+04 6.10E+04 9.23%
Interday assay (14) 6.43E
+05
1.36E+04 5.10E+04 7.94%
QC samples were analysed on fourteen occasions; 3 at the start and the end of the
analysis, and one after every 9 samples; a blank was also analysed after every 3 samples.
The QC results show that the LC method is accurate with an intra-day assay %CV of 9.23
and inter-day assay %CV of 7.94. The QC sample is a pooled extract of all the samples
from the study.
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The higher levels of POVPC and lower antioxidant potential, FRAP,
that we measured here in AD subjects compared to their age-matched
controls support the existing evidence for increased systemic oxidative
damage to macromolecules in AD [1,8,22,34]. The FRAP, POVPC level
and IsoP concentration in AD patients' serum was unchanged after six
months of carotenoid intervention using 10 mg meso-zeaxanthin;10 mg
lutein; 2 mg zeaxanthin. However, in control subjects a signiﬁcant
increase in POVPC level but not IsoP concentration was observed after
six months of carotenoid intervention. Several antioxidants, e.g.
vitamin C, may also act as pro-oxidants at high concentrations and
Fig. 2. (a) Box plot (inter-quartile range, with whiskers showing the minimum to maximum range) of ferric reducing antioxidant potential (FRAP) in control and AD groups at baseline
(p=0.003) (b) Box plot showing the serum 8-isoprostane (IsoP) concentration in control and AD groups at baseline (p=0.717). (c) Box plot showing the serum POVPC levels in control
and AD groups at baseline (##, p=0.017). (d) Box plot showing the serum POVPC levels in AD patients being treated with cholinesterase inhibitor (+CI) and AD patients without
cholinesterase inhibitor (-CI) treatment (p=0.26). (e) Scatter plot showing the relationship between cognitive function and lipid oxidation with no correlation existing between MMSE
score and serum FRAP r=−0.19. (f) Scatter plot showing the relationship between cognitive function and lipid oxidation with no correlation existing between MMSE score and serum
IsoP concentration, r=−0.08. (g) Scatter plot showing the relationship between cognitive function and lipid oxidation as MMSE score and POVPC intensity, r=−0.37, p=0.04 and with
MMSE score explaining 13.7% of the variation in POVPC levels. (h) Scatter plot showing the relationship between cognitive function and lipid oxidation with no correlation existing
between SVF score and POVPC, r=−0.05. (i) Scatter plot showing the relationship between cognitive function and lipid oxidation with no signiﬁcant correlation existing between FAS
score and POVPC, r=−0.27.
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there remains an optimal antioxidant concentration in serum to
maintain reducing activity. We are not sure if this is responsible for
the high levels of POVPC and lack of change to FRAP in the control
subjects after carotenoid supplementation but we expected supplemen-
tation with macular carotenoids to beneﬁt AD patients by reducing
POVPC level and increasing FRAP based on evidence of clinical
improvement in vision after using the same supplement (see [25]). It
was shown previously that carotenoids have contrasting eﬀects on rates
of peroxidation that relate to interaction with membrane lipids. Using
x-ray diﬀraction studies, lutein and zeaxanthin have been shown to
alter phospholipid acyl chain organisation which correlated with lipid
peroxidation [35]. However, astaxanthin did not modify the phospho-
lipid structure in the membrane and it was an antioxidant [35]. FRAP
analysis did not detect an increase in total antioxidant potential on
supplementation, suggesting that carotenoid supplements do not con-
tribute signiﬁcantly to serum antioxidant activity and therefore are not
likely to have direct eﬀects on oxidative stress in this AD population.
There are ~20 diﬀerent carotenoids in human plasma with lyco-
pene, α- and β-carotene, zeaxanthin, lutein and β-cryptoxanthin being
the most abundant. AD patients have low plasma carotenoid concen-
trations and recent evidence has shown that AD is more prevalent in
patients with age-related macular degeneration (AMD). This led to the
hypothesis that dietary supplementation with macular carotenoids may
delay progression of both AMD and AD. While 10 mg meso-zeax-
anthin;10 mg lutein; 2 mg zeaxanthin supplementation increases total
serum carotenoid concentrations in AD (22), it has not led to any
change in AD serum POVPC level, FRAP or improvement in cognitive
performance. One potential explanation is that those foods which are
enriched in carotenoids may deliver additional essential phytonutrients
that are not included in the supplement formulation; the serum
carotenoid concentrations used here may be a correlate of lower
nutrient intake rather than act an important bioactive for reducing
phospholipid oxidation. Fruits and vegetables are the best dietary
sources of protective phytochemicals and antioxidants [36]. Additional
phytochemicals such as astaxanthin may either reduce the formation of
POVPC directly or may operate in synergy with the carotenoid
supplement constituents 10 mg meso-zeaxanthin;10 mg lutein; 2 mg
zeaxanthin as chain breaking antioxidants. Carotenoids are reported as
anti-inﬂammatory, antioxidant, functional and structural enhancers of
the synaptic membrane and gap junction communication; protective
against oxidative insult, malignant transformation, light related da-
mage, mutagenesis and chemically-induced neoplasia in the brain
[21,37].
We did not see any signiﬁcant diﬀerence between serum IsoP
concentration in AD patients compared to healthy controls at baseline
and IsoP was unrelated to cognitive performance measured by MMSE.
Our results from the IsoP data contradict previous ﬁndings that IsoP is
higher in AD compared to controls [3,38]. The lack of eﬀect seen here is
most likely due to the limited sensitivity of IsoP and the high degree of
variance in serum IsoP concentration within groups.
IsoP can also be generated enzymatically and systemically by
multiple tissues [39] and the proportion of IsoP that is attributable to
free radical damage is debated. For this reason, the analysis of POVPC is
preferred over IsoP as a peroxidation biomarker, since it is only
generated via a non-enzymatic mechanism.
Our validated method has deﬁned the range and variance of POVPC
in people with and without AD. Using this information to calculate
power using G*Power [40], a total sample size of 102 (51 patients and
51 healthy controls) is required to attain a power of 80% with p<0.05.
We will be validating our ﬁndings in a larger cohort that has
commenced on Macushield™ with participants who have mild dementia
and who are treated for longer than six months.
Our study contributes to a growing body of research that highlights
oxPLs as biomarkers of human pathologies. OxPLs are widely reported
to be inﬂammatory through engagement with Toll-like receptors on
macrophages and activation of the inﬂammasome [41,42]. Others have
Fig. 2. (continued)
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reported that oxidised lipids including POVPC can aﬀect microvascular
endothelial barrier function and are therefore likely to impair the
functions of the blood brain barrier [23,43]. We have previously shown
that oxidised lipids can increase amyloid production by neuronal cells
[22,44]. It remains to be determined whether OxPL such as POVPC are
important in the pathway to disease development and are eﬀective
biomarkers of early disease and mild cognitive impairment.
Fig. 3. Box plots (inter-quartile range, with whiskers showing the minimum to maximum range) where 0, baseline; 6, six months, C, control group; A, AD group; P, placebo intervention; C,
carotenoid intervention; (a) Animal semantic ﬂuency (SVF) score in control subjects and AD patients at baseline and at 6 months of placebo/carotenoid intervention; (b) Phonemic ﬂuency
score (FAS) in control subjects and AD patients at baseline and at 6 months of placebo/carotenoid intervention; (c) Ferric reducing antioxidant potential (FRAP) in control and AD groups
at baseline and at 6 months of placebo/carotenoid intervention. (d) Serum concentrations of 8-isoprostane (IsoP) in control and AD groups at baseline and after 6 months of placebo/
carotenoid intervention; (e) Serum POVPC in control and AD groups at baseline and after 6 months of placebo/carotenoid intervention. POVPC levels between control subjects at baseline
and after 6 months carotenoid supplementation (#, p=0.03 compared to baseline).
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5. Conclusion
We have described a reliable and sensitive MS method to measure
POVPC that has been employed successfully to analyse peroxidative
damage to phospholipids in serum. Using this method, the peroxidised
phospholipid POVPC was found to be higher in AD patients and was
correlated with cognitive performance. In our study of 37 subjects,
supplementation with carotenoids (10 mg meso-zeaxanthin, 10 mg
lutein, 2 mg zeaxanthin) for six months in AD had no eﬀect on patients’
cognitive performance or serum POVPC level.
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